Physician profile
Thomas L Johnson
NPI 1255399226
$361,104.47
in general payments reported to CMS, 2019-2025
32 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $13K · 2021: $24K · 2022: $48K · 2023: $138K · 2024: $111K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Food and Beverage: $11K · Travel and Lodging: $6,820 · Consulting Fee: $1,625 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $241,830.00 |
| Food and Beverage | $10,933.00 |
| Travel and Lodging | $6,819.85 |
| Consulting Fee | $1,625.00 |
| Education | $148.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $157,126.94 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $145,229.28 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Optinose US, INC. | $48,387.11 | 2019-2024 | |
| Amgen INC. | $2,959.41 | 2022-2023 | Tezspire |
| Genzyme Corporation | $1,336.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,170.48 | 2021-2025 | Glassia, Cuvitru, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $882.86 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $564.53 | 2019-2024 | |
| Covis Pharma Gmbh | $519.33 | 2019-2023 | |
| Biocryst US Sales Co., LLC | $411.82 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $380.46 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $255.11 | 2020-2025 | Hizentra, Haegarda |
| Genentech USA, INC. | $242.41 | 2019-2023 | Xolair |
| Pfizer INC. | $193.66 | 2019-2025 | |
| Abbvie INC. | $192.31 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $182.32 | 2019-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $179.78 | 2020-2024 | Ruconest |
| Octapharma USA, INC. | $167.89 | 2022-2024 | Octagam Immune Globulin (Human), Cutaquig, Panzyga |
| Aimmune Therapeutics, INC. | $126.40 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.16 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2023 | |
| Alk-Abello, INC | $65.63 | 2020-2022 | |
| Mylan Specialty L.P. | $58.79 | 2023 | Yupelri |
| Leo Pharma INC. | $54.43 | 2022-2023 | Adbry |
| Blueprint Medicines Corporation | $53.12 | 2024 | Ayvakit |
| Greer Laboratories, INC. | $51.38 | 2024-2025 | Oralair |
| Teva Pharmaceuticals USA, INC. | $38.01 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $21.86 | 2025 | Neffy |
| Eyevance Pharmaceuticals LLC | $21.79 | 2020 | |
| Merck Sharp & Dohme LLC | $18.08 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.